HEART TRANSPLANTATION: Edited by Ugolino LiviAntibody-medicated rejection after heart transplantation diagnosis and clinical implicationsNguyen, Vidang P.; Kobashigawa, Jon A.Author Information Cedars-Sinai Heart Institute, Los Angeles, California, USA Correspondence to Jon A. Kobashigawa, MD, 127 S. San Vicente Blvd, Third Floor Cardiology A3107, Los Angeles, CA 90048, USA. Tel: +1 310 248 8310; fax: +1 310 248 8338; e-mail: email@example.com Current Opinion in Organ Transplantation: June 2020 - Volume 25 - Issue 3 - p 248-254 doi: 10.1097/MOT.0000000000000754 Buy Metrics Abstract Purpose of review The present article will review the diagnosis of antibody-mediated rejection in heart transplant recipients and further explore the clinical implications. Recent findings Improved diagnostic techniques have led to increased recognition of antibody-mediated rejection and better understanding of the long-term consequences in heart transplant recipients. Endomyocardial biopsy remains the gold standard for the diagnosis of antibody-medicated ejection; however, several advances in molecular testing have emerged, including the use of gene expression profiling, messenger RNA, and microRNA. Routine surveillance of donor-specific antibodies identifies recipients at high risk for graft compromise. Additionally, new monoclonal antibody therapies have broadened our repertoire in the treatment of rejection. Summary Advances in molecular testing for antibody-mediated rejection may improve the associated long-term complication, while minimizing risk to the patient. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.